CRT Versus Surgery for Retroperitoneal or Paraaortic Lymph Node Recurrence of CRC

Fudan University180 enrolled

Overview

The study aims to compare the effects of chemoradiation versus radical surgery in treating retro-peritoneal or para-aortic lymph node metastasis in colorectal cancer. By prolonging patients' progression-free survival, local control rate and overall survival, investigators can conclude the best regimen for colorectal cancer patients.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

180

Conditions

Colorectal Cancer Retroperitoneal Lymph Node Metastasis Para-aortic Lymph Node Metastasis

Interventions

lymphadenectomyPROCEDURE

The retroperitoneal lymphadenectomy includes all lymph, fat, and connective tissue in the retroperitoneal space.

chemoradiotherapyRADIATION

Radiation therapy is highly appropriate, based on the characteristics of the lesion and the surrounding critical organs, and select IMRT or stereotactic radiotherapy (SBRT).

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * A medical history of colorectal cancer * Pathological or clinical diagnosis of retroperitoneal/para-vascular lymph node metastases, and located below the level of renal veins. * The treatment target is no evidence of disease (NED), including 3 cohorts: A. Initial treatment (primary lesion + retroperitoneal LN oligometastasis); B. Postoperative retroperitoneal/paravascular LN oligometastase; C. Postoperative retroperitoneal/paravascular LN metastasis with other organ metastases (up to NED) * ECOG PS 0-2 * Ability to follow the program during the study period * Signing written informed consent Exclusion Criteria: * Retroperitoneal LN metastasis is above the level of the renal vein. * Unable to reach NED. * Previous pelvic radiotherapy, the field of irradiation overlaps with this time. * Pregnancy or breastfeeding women. * Those with other history of malignant disease in the last 5 years, except for cured skin cancer and cervical carcinoma in situ. * If there is an uncontrolled history of epilepsy, central nervous system disease or mental disorder, the investigator may determine that the clinical severity may hinder the signing of informed consent or affect the patient's oral medication compliance. * Clinically severe (ie, active) heart disease, such as symptomatic coronary heart disease, New York Heart Association (NYHA) class II or more severe congestive heart failure or severe arrhythmia requiring medication intervention, Or a history of myocardial infarction in the last 12 months * Organ transplantation requires immunosuppressive therapy * Severe uncontrolled recurrent infections, or other serious uncontrolled concomitant diseases * Subjects Blood routine and biochemical indicators do not meet the following criteria: hemoglobin ≥ 90g / L; absolute neutrophil count (ANC) ≥ 1.5 × 109 / L; platelets ≥ 100 × 109 / L; ALT, AST≤2.5 times normal upper limit; ALP≤2.5 times normal upper limit; serum total bilirubin \<1.5 times normal upper limit; serum creatinine \<1 times normal upper limit; serum albumin ≥30g/L

Locations (1)

Cancer Hospital, Fudan University

Shanghai, Shanghai Municipality, China

RECRUITING

Outcomes

Primary Outcomes

Progression-free survival

The length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse. In a clinical trial, measuring the progression-free survival is one way to see how well a new treatment works. Also called PFS.

Time frame: From date of randomization until the date of disease progressed for any reason, assessed up to 5 years

Secondary Outcomes

overall survival

The length of time from either the date of diagnosis or the start of treatment for a disease, such as cancer, that patients diagnosed with the disease are still alive. In a clinical trial, measuring the overall survival is one way to see how well a new treatment works. Also called OS.

Time frame: From date of randomization until the date of death from any cause, assessed up to 5 years

local control rate

no recurrence of the retroperitoneal or paraaortic lymph node region.

Time frame: From date of randomization until the date of disease recurrece, assessed up to 5 years

Central Contacts

Ji Zhu, MD

CONTACT

+86-2164175590 leo.zhu@126.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.